Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. This landscape is rapidly changing.

RNA 52

RNA Genome Genomics DNA 52

pharmaphorum

JANUARY 26, 2023

The combination of advanced long- and short-read genomic sequencing technologies holds great promise for precision oncology, and in the development of mRNA vaccines for certain cancers. With its already strong genomics foundation, the passing of this bill will cement the UK as a world leader in genomics.

Genome 129

Genome Genomics Genome Project Genetics 129

Drug Discovery World

NOVEMBER 7, 2022

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies – precision medicines. DDW’s Megan Thomas observes developments of accessibility in this sector and the potential impact. . The origins . The current landscape .

Genome 98

Genome Genomics Development Genetics 98

Drug Discovery World

MARCH 13, 2024

Thanks to significant investment by the government into research and development, Singapore has become a leading centre for biomedical sciences in Asia. Following this, a medical innovation and development centre, Biopolis Hub, was opened in 2005. UK-based molecular diagnostics group Yourgene operates in Singapore.

Life Science 69

Life Science Genome Genomics Research 69

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

OCTOBER 6, 2022

In pursuit of this, the number of new therapeutics in development has boomed. New classes of therapies have added to this growth, including immune checkpoint inhibitors and genome targeted therapies. Both the binary and quantitative have relied on measurement of protein, DNA, and more recently, RNA.

Medicine 52

Medicine Clinical Trials Clinical Trials Genome 52

Roots Analysis

AUGUST 28, 2022

As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players.

Genome 52

Genome Genomics RNA Genome Project 52